ArticleDiabetology & metabolic syndrome2026
Acute renoprotective effects of dapagliflozin monotherapy on albuminuria and metabolic derangements in newly diagnosed type 2 diabetes mellitus: a quasi-experimental study.
Article in Diabetology & metabolic syndrome, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiabetic kidney disease (DKD) is a globally prominent microvascular sequela of Type 2 Diabetes Mellitus (T2DM), making effective early prevention paramount. The well-established cardiorenal benefits of sodium-glucose co-transporter 2 inhibitors (SGLT2i) are largely derived from studies on patients with T2DM. Clear evidence is lacking to support the use of SGLT2i as a first-line monotherapy in newly diagnosed T2DM patients who have not yet initiated other glucose-lowering or protective agents. This study aimed to fill this knowledge gap by assessing the acute impact of Dapagliflozin on reducing albuminuria and correcting metabolic derangements during this critical early disease window to halt disease progression at its onset.
methodsThis quasi-experimental study conducted over a 3-month intervention period, included 133 newly diagnosed T2DM patients (76 males, 57 females) with evidence of micro- or macro-albuminuria. All patients were treated with Dapagliflozin 10 mg/day, primary and secondary endpoints were assessed by cardiorenal markers (albumin-to creatinine ratio (ACR) and calculated glomerular filtration rate (GFR)), metabolic marker (HbA1c), Anthropometric parameters (BMI and blood pressure), were measured at baseline and follow-up, Paired t-tests were used for pre- and post-intervention analysis.
resultsDapagliflozin significantly improved both metabolic and renal markers within the short follow-up period. The primary outcome, ACR, declined markedly from 108.44 mg/g to 65.79 mg/g (P < 0.001), representing a mean relative reduction of approximately 40%. Glycemic control was rapidly achieved, with a mean HbA1c drop from 9.04% to 7.31% (P < 0.001). While calculated GFR remained stable overall, a significant reduction in systolic blood pressure was also observed (P < 0.001).
conclusionDapagliflozin demonstrates a rapid and multi-organ protective effect when introduced early in T2DM, achieving potent reduction in albuminuria and excellent glycemic control while preserving kidney function stability. These findings strongly support the integration of SGLT2i as a first-line therapy to mitigate cardiorenal risk from the earliest stages of T2DM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.